Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
| 18.98 | |
| 18.8 | |
| - | |
| 20.26 | |
| 18.73 | |
| 5.12-23.5 | |
| 1 841 M | |
| 93 410 K | |
| 0 | |
| -0.33 | |
| 0.146 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
There’s no denying we’re in a bull market. Over the past 18 months, with only a few blips, the markets have been trending upwards – and usually at a fast clip. Such rallies inevitably raise a fe...
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ev...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
